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Abstract
Background: Echocardiographic evaluation of left ventricular ejection fraction (LVEF) is used 
in the risk stratification of patients with an acute myocardial infarction (AMI). However, the 
prognostic value of the Tei index, an alternative measure of global cardiac function, in AMI 
patients is not well established.
Methods: We conducted a systematic review, using MEDLINE and EMBASE, to evaluate the 
prognostic value of the Tei index in predicting adverse outcomes in patients presenting with 
AMI. The data was collected and narratively synthesised.
Results: A total of 16 studies were including in this review with 2886 participants (mean 
age was 60 years from 14 studies, the proportion of male patients 69.8% from 14 studies). 
Patient follow-up duration ranged from during the AMI hospitalisation stay to 57.8 months. 
Tei index showed a significant association with heart failure episodes, reinfarction, death 
and left ventricular thrombus formation in 14 out of the 16 studies. However, in one of 
these studies, Tei index was only significantly predictive of cardiac events in patients 
where LVEF was <40%. In two further studies, Tei index was not associated with predicting 
adverse outcomes once LVEF, left ventricular end-systolic volume index and left ventricular 
early filling time was taken into consideration. In the two remaining studies, there was no 
prognostic value of Tei index in relation to patient outcomes.
Conclusions: Tei index may be an important prognostic marker in AMI patients, however, 
more studies are needed to better understand when it should be used routinely within 
clinical practice.
Introduction
First described in 1995 (1), the Tei index, also known 
as a myocardial performance index, is a ratio of systolic 
and diastolic time intervals which can be easily obtained 
from Doppler echocardiography. This timing ratio, 
characterised by the sum of the isovolumetric contraction 
time and isovolumetric relaxation time divided by the 
overall ejection time, has been well validated in the 
assessment of overall global myocardial performance in 
both adult and paediatric populations (1, 2). Although 
Tei index is not a frequently used measurement in 
assessing cardiac function in current clinical practice, 
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reliable and reproducible measurement in patients with 
congestive heart failure, congenital heart disease and 
cardiac rejection post-transplantation (3). Tei index has 
also been shown to have prognostic value in patients with 
cardiac amyloidosis and dilated cardiomyopathy (4, 5).
An acute myocardial infarction (AMI) is a leading 
cause of morbidity and mortality worldwide (6) with 
known complications including congestive heart failure, 
functional and structural myocardial abnormalities, 
reinfarction and death. In the setting of an AMI, 
echocardiography is a well-established risk stratification 
tool (7, 8). Consequently, echocardiographic assessment 
in the early post-AMI stage forms part of national 
and international guidelines (9, 10). An important 
echocardiographic measurement for post-AMI patients is 
the assessment of left ventricular systolic function via left 
ventricular ejection fraction (LVEF) which is well associated 
with short-term and long-term outcomes (11, 12, 13). 
However, it is well recognised that systolic and diastolic 
function are tightly connected at a cellular, myocardial 
and hemodynamic level (14). As such, Tei index, which 
considers both contraction and relaxation timing 
intervals, may provide important prognostic information 
in patients presenting with AMI which may go unmissed 
with the isolated evaluation of LVEF. Furthermore, the Tei 
index is less affected by image quality compared to LVEF 
and GLS which makes the index an attractive parameter 
for the assessment of global left ventricular function.
Studies in the literature evaluating the prognostic 
value Tei index after AMI are inconsistent with studies 
reporting an association between a greater Tei index 
and adverse events (15, 16, 17, 18). Whilst other studies 
either conclude there to be no association (19) or, that Tei 
index offer no additional benefit over the more routinely 
used LVEF measurement (20). In view of the importance 
of understanding the prognostic value of the Tei index 
in AMI patients and the inconsistencies reported, we 
conducted a systematic review of the literature to evaluate 
what is currently known.
Methods
We conducted a systematic review to evaluate the current 
literature on the prognostic value of Tei index in patients 
presenting with an AMI. Tei index was defined as per 
Fig. 1. Study inclusion criteria included: retrospective 
cohort studies, prospective cohort studies and matched 
control studies. Excluded criteria consisted of conference 
abstracts, animal studies, case studies, case series, 
studies using bare-metal stents used as part of the AMI 
treatment plan. Studies that analysed the same cohort 
were also excluded to avoid duplication of results.
A search of MEDLINE and EMBASE was performed 
on OVID using the search terms ‘Tei index’, ‘myocardial 
performance index’, ‘acute coronary syndrome’, ‘acute 
myocardial infarction’, ‘STEMI’ in April 2020. The search 
results were independently reviewed for inclusion by two 
reviewers (SB and CSK). Full text of potentially relevant 
studies was downloaded and reviewed for final inclusion. 
Data extractions were performed by two independent 
reviewers (SB and CSK). Extracted information included 
study design, year, country the study was conducted 
in, number of participants, mean age of participants, 
percentage of male participants, participant inclusion 
criteria, echocardiographic findings, prognostic outcomes/
clinical outcomes of Tei index. The Newcastle–Ottawa 
quality assessment scale was used to assess the quality of 
each included study (21). The Newcastle-Ottawa scale was 
incorporated into this review as it enables a standardised 
and comprehensive assessment of nonrandomised 
studies to be quality assessed against (21). Results from 
the extractions are presented in tables. The results were 
narratively synthesised.
Results
Our search results yielded 144 potential inclusions and 
after detailed screening and review, a total of 16 studies 
Figure 1
Schematic representation of Tei index.
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were included in the review (Fig. 2) (6, 14, 15, 16, 17, 
18, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29). These studies 
included 14 cohort studies and 2 matched control 
studies (Table 1). In total, 15 out of the 16 studies that 
reported when the studies had been conducted showed 
that the studies were performed between 1995 and 2015. 
The studies took place around the world including 
Denmark, Norway, Egypt, Japan, Israel, Brazil, Poland, 
Turkey, Sweden and Romania. Overall, there were a total 
of 2886 participants with individual study participant 
numbers ranging from 44 to 417. From 14 studies that 
reported mean age of participants, the average overall age 
was 60 years. From 14 studies which reported participant 
sex, the overall mean percentage of male participants was 
69.8%. Only 7 of the 16 included studies, included patients 
with first AMI. Detailed echocardiographic parameters 
that were reported in each of the included studies are 
shown in Supplementary Table 1 (see section on 
supplementary materials given at the end of this article).
All studies used transthoracic echocardiography to 
assess Tei index, 3 of which used tissue Doppler image 
with the remaining studies using trans-mitral and left 
ventricular outflow time intervals obtained from either 
continuous or pulsed wave Doppler studies. Of the 16 
studies, 10 included all coronary territory AMI patients, 
two studies included only anterior AMI patients, one 
included only anteroseptal AMI patients, the three studies 
did not comment on the coronary territory. Twelve 
studies indicated that the Tei index measurements were 
undertaken during the same hospitalisation of the AMI. 
However, the timing of the Tei index measurement 
Search of MEDLINE and EMBASE 
yielded 144 studies.
Studies were excluded for the following 
reasons:
· 52 Conference abstracts.
· 1 Editorial.
· 68 studies not involving acute ST 
myocardial infarcon 
parcipants.
· 7 Animal studies.
16 studies included. 
Figure 2
Flow diagram of studies inclusion.
Table 1 Description of studies.
Study ID





age Male % Inclusion criteria Exclusion criteria
Abuomara 2018 Prospective cohort 
study; Egypt; 
2014–2015
60 54 70 Patients with first  
acute anterior 
STEMI treated  
with primary PCI.
Known dilated cardiomyopathy, 







386 62 75 Patients with  
STEMI treated  
with primary PCI.
Poor quality echocardiography 
images.
Hole 2003 Prospective cohort 
study; Norway; 
1995–1997
71 65 73 Patients in sinus  
rhythm with AMI  
without heart 
failure.
Unstable angina requiring PCI, 
CABG, heart failure, AF, comorbid 
non-cardiac disease reducing life 
expectancy <2 years.
Karvounis 2004 Matched control 
study; Greece; 
unclear
68 53 78 Patients who 
survived AMI  
who received 
thrombolysis. 
Previous Q wave myocardial 
infarction, AF, moderate to severe 
mitral regurgitation, severe aortic 
stenosis.
Møller 2001 Prospective cohort 
study; Denmark; 
unclear
125 68 Unclear Patients with  
first AMI.
Aortic stenosis, implanted 
pacemaker and dementia.









Rahman 2009 Prospective cohort 
study; Pakistan; 
2006–2007
202 Unclear 78 Patients  
with AMI.
Significant mitral regurgitation or 
aortic stenosis, inadequate echo 
images, congenital heart disease.
(Continued)
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age Male % Inclusion criteria Exclusion criteria
Sasao 2004 Matched control 
study; Japan; 
2000–2001
53 63 72 Patients with first 
AMI treated with 
primary PCI.
Slow flow after post-PCI, presence 
of mechanical complications, 
previous myocardial infarction, AF, 




Cohort study; Israel; 
unclear
417 62 78 Patients  
with AMI.
Patients who did not have echo 
evaluation.
Souza 2011 Prospective cohort 
study; Brazil; 
unclear
95 58 67 Patients with  
first STEMI.
Previous AMI, early reinfarction, 
early reinfarction, in-hospital 
death, previous CABG or PCI, left 
bundle branch block, non-sinus 
rhythm, valvular heart disease, 
dilated cardiomyopathy, poor 
echocardiography images.
Szymanski 2002 Prospective cohort 
study; Poland; 
unclear
90 58 71 Patients who  
were hospital  
survivors  
of AMI.




Uzunhasan 2006 Prospective cohort 
study; Turkey; 
2001–2002




AF, permanent pacemaker, 
dementia, aortic stenosis, 
inappropriate Doppler recordings, 
chronic obstructive pulmonary 
disease.
Westholm 2013 Prospective cohort 
study; Sweden; 
2006–2008
227 67 76 Patients admitted  
with an AMI.
None.
Yilman 2004 Prospective cohort 
study; Turkey; 
unclear
92 58 88 Patients with first  
anterior AMI.
Rhythm and conduction 
abnormalities, prior AMI, 
cardiomyopathy, valvular heart 
disease, lung disease, pulmonary 
hypertension, patients who 
underwent PCI, poor 
echocardiography images
Yuasa 2005 Cohort study; Japan; 
unclear
80 64 78 Patients with first  
anteroseptal AMI.
Multiple infarctions, congenital, 
pericardial and organic valvular 
heart disease.
Zamfir 2016 Prospective cohort 
study; Romania; 
2015–2016
44 63 70 Patients with acute 
STEMI treated 
with primary PCI.
Previous history of cardiac or 
pulmonary disease.
AF, atrial fibrillation; AMI, acute myocardial infarction; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; STEMI, ST elevation 
myocardial infarction.
Table 1 Continued.
in relation to the AMI event varied within 1 h of the 
angioplasty procedure to within 7 days of AMI. Table 2 
shows the quality assessment which was undertaken on 
all of the included studies in this review. The Newcastle-
Ottawa Quality assessment tool indicated that 3 out of 16 
studies were of fair quality while the remaining studies 
were of good quality. Of the 16 included studies, 14 studies 
indicated that a high Tei index value showed a significant 
association with heart failure episodes, reinfarction, 
death and left ventricular thrombus (Table 3). These are 
discussed separately below.
Tei index and mortality studies
In the study by Karvounis et al., Tei index was greater 
among patients with Killip class II and III compared to 
Killip class I at both 1 day follow-up and 1 month follow-up. 
The mortality rate at 1 year was higher with Killip class II 
and III compared to class I (24). For survival, Møller et al. 
found that survival at 1 year was 89% among patients 
with a Tei index <0.63 compared to 37% with a Tei index 
≥0.63. Here, Tei index was associated with an increased 
risk of cardiac death (RR 5.6 95% CI 2.4–13.0) (15). 
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Møller  et  al. also showed that at a median follow-up 
duration of 34 months, relative to a Tei index of <0.46, 
there was a two-fold increase in the risk of death with a 
Tei index value of between 0.46 and 0.68 and a four-fold 
increase in the risk of death with a Tei index value >0.68 
(15). Szymanski  et  al. found that a Tei index >0.55 was 
associated with a four-fold increase in the risk of cardiac 
death and nonfatal recurrent myocardial infarction (14). 
Uzunhasan et al. found that Tei index was greater among 
patients with death and heart failure (26).
Tei index and heart failure studies
Abuomara  et  al. evaluated the value of a Tei index 
>0.73 compared to a LVEF ≤33% and found that the 
Tei index was more sensitive (78.3% vs 56.5%) with 
similar specificity (94.6% vs 94.6%) for in-hospital 
heart failure after AMI (6). Sasao et al. concluded that a 
greater Tei index (reported as >0.70) was correlated with 
the development of heart failure episodes (OR 14.139 
95% CI 1.269–157.553) (18). Schwammenthal  et  al. 
found that Tei index ≥0.52 was not predictive of adverse 
outcomes whilst an LVEF <40% was associated with 
adverse outcomes (19). Souza et al. found that an LVEF 
≤45% was associated with increased odds of in-hospital 
heart failure but only amongst patients ≥60 years of age 
with a Tei index ≥0.57 (25).
Tei index and composite adverse outcomes
Biering Sørensen et  al. reported that a greater Tei index 
value (0.59 ± 0.16 vs 0.52 ± 0.13, P < 0.001) was associated 
with major adverse outcomes including congestive heart 
failure, reinfarction and mortality (22). Similarly, over 
a 2-year follow-up duration Hole  et  al. found that Tei 
index was a better predictor of major adverse outcome 
compared to baseline LVESI and EDT but Tei index was 
not a better predictor of heart failure or death (23). 
Rahman  et  al. found that a Tei index value >0.40 had 
better sensitivity (86% vs 65%), specificity (82% vs 50%) 
and accuracy (83% vs 58%) compared to LVEF <40% for 
predicting cardiac complications including cardiogenic 
shock, revascularisation, readmissions, congestive heart 
failure and advanced atrioventricular heart block (17). 
Table 2 Study quality assessment using Newcastle Ottawa Scale.








Abuomara 2018 Within 24 h of presentation **** * ** Good quality
Biering-Sørensen 2013 Within 5 days of admission *** ** *** Good quality
Hole 2003 Between 2 and 7 days after AMI *** – ** Fair quality
Karvounis 2004 Within 24 h of admission and 
repeated 1 month after AMI
*** * ** Good quality
Møller 2001 Within 24 h of admission,  
then on day 5, 1 and  
3 months post-AMI
*** – * Fair quality
Møller 2003 Within 6 days of AMI **** * *** Good quality
Rahman 2009 Unclear *** – ** Good quality
Sasao 2004 Within 1 h of angioplasty *** * *** Good quality
Schwammenthal 2003 Within 24 h of hospital admission **** * *** Good quality
Souza 2011 Within 24 h of arrival at  
coronary care unit, within  
48 h of chest pain
*** * ** Good quality
Szymanski 2002 14 ± 2 days post-AMI *** ** ** Good quality
Uzunhasan 2006 Within 24 h of admission *** – ** Good quality
Westholm 2013 Median time 3(2–4) days from 
admission
*** – *** Good quality
Yilman 2004 Within 24 h of admission *** * *** Good quality
Yuasa 2005 At time of admission *** * *** Fair quality
Zamfir 2016 Within hospitalisation stay of AMI *** * ** Good quality
aSelection domain based on: (1) Representativeness of exposed cohort, (2) Selection of the non-exposed cohort, (3) Ascertainment of exposure, 4) 
Demonstration that outcome of interest was not present at the start of the study; a star (*) is awarded for each of the criteria meet, a maximum of 4 stars 
can be awarded for this domain; bComparability domain based on: comparability of cohorts on the basis of the design of analysis – *Control for age, 
**Control for other factors; cOutcome domain based on: (1) Assessment of outcome, (2) Was follow-up long enough for outcomes to occur, (3) Adequacy 
of follow-up of cohorts. 
AMI, acute myocardial infarction; LV, left ventricle.
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Table 3 Tei index cut off values, outcomes and prognostic use of Tei index.
Study ID
Tei index  
abnormal cut  
off values Tei index and outcomes Tei index prognostically useful?
Abuomara 2018 >0.73 Tei Index with and without heart failure:
0.88 ± 0.18 vs 0.58 ± 0.11, P = 0.0001.
Heart failure with Tei Index >0.73:  
sensitivity 78.3%, specificity 94.6%.




0.59 ± 0.16 Tei Index with and without major  
adverse outcome: 0.59 ± 0.16 vs  
0.52 ± 0.13, P<0.001.
Yes, able to predict development 
of heart failure, future 
hospitalisation, reinfarction and 
mortality
Hole 2003 N/A Tei Index was a significant predictor of major  
adverse outcome, but not for the development  
of heart failure or death.
No, not able to predict heart 
failure episodes.
Karvounis 2004 N/A Control vs Killip class I vs Killip class II and III:
Tei Index at day 1: 0.330 ± 0.080 vs  
0.344 ± 0.084 vs 0.686 ± 0.120, P < 0.0001.
Tei Index At 1 month: 0.330 ± 0.080 vs  
0.329 ± 0.080 vs 0.649 ± 0.110, P < 0.0001.
Yes, associated with mortality.
Møller 2001 >0.63 One-year survival in patients with Tei Index 
 <0.63 was 89% compared to 37% in patients  
with index ≥0.63, P < 0.0001.
Cardiac death with Tei Index >0.63:  
RR 5.6 (2.4–13.0), P < 0.0001.
Yes, able to predict LV dilatation 
and mortality.
Møller 2003 N/A Multivariable predictors of all-cause  
deaths according to Tei index:
Tei index < 0.46: ref.
Tei index 0.46–0.55: aRR 2.1 (1.2–3.6), P = 0.001.
Tei index 0.56–0.68: aRR 2.3 (1.5–3.9), P = 0.001.
Tei index > 0.68: aRR 4.0 (2.1–11.6), P < 0.0001.
Yes, independent predictor of 
morality. 
Rahman 2009 >0.40 Prediction of cardiac complications:
Tie index of >0.40 sensitivity 86%,  
specificity 82%, accuracy 83%.
Tei Index and hazards ratios for complications:
Cardiogenic shock: HR 2.5 (1.7–3.6), P = 0.008.
Cardiac death: HR 2.0 (1.4–2.9), P = 0.30.
Revascularisation: HR 2.0 (1.6–2.7), P = 0.023.
Readmission: HR 1.3 (1.1–1.4), P = 0.016.
Congestive heart failure: HR 2.0 (1.6–2.7), P = 0.041.
Secondary arrhythmias: HR 1.5 (1.1–1.9), P = 0.32.
Advanced atrioventricular block: HR 1.4 (1.2–1.7), 
P = 0.03.
Yes, independent predictor of 
cardiac complications (excluding 
secondary arrhythmia’s).
Sasao 2004 >0.70 Tei index significantly higher in acute  
myocardial infarction patient’s vs controls:  
0.630 vs 0.375, P < 0.0001.
Tei index >0.70 was significantly correlated with  
cardiac events (cardiac death or congestive heart  
failure): OR 14.139 (1.269–157.553), P = 0.0313.
Yes, significantly associated with 
development of heart failure and 
mortality but only when LVEF 
<45% in patients >60 years.
Schwammenthal  
2003
>0.52 Multivariable predictor of death, congestive  
heart failure and reinfarction:
Tei Index ≥0.52: OR 1.09 (0.59–2.14).
LVEF <40%: OR 3.82 (2.15–6.87).
No, not able to predict 
development of heart failure, 
reinfarction or mortality.
Souza 2011 Independent predictor of in-hospital  
congestive heart failure events:
Left ventricular ejection fraction ≤45%: OR  
17.0 (4.1–70.8), P < 0.0001.
Age ≥60 and Tei index <0.57: OR 0.5 (0.1–4.1).
Age ≥60 and Tei index ≥0.57: OR 13.7  
(2.7–68.6), P = 0.02
Yes, independent predictor for 
development of in-hospital heart 
failure.
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
https://erp.bioscientifica.com © 2020 The authors
 Published by Bioscientifica Ltdhttps://doi.org/10.1530/ERP-20-0017
S Bennett et al. Prognostic value of Tei index 
in AMI
557:4
Westholm  et  al. found that Tei index did not have a 
better AUC for predicting adverse outcomes compared 
to Simpson’s biplane LVEF (20). In the evaluation of left 
ventricular intra-cavity thrombus formation, Yilmaz et al. 
reported that a Tei index value >0.60 had good sensitivity 
(81%) and specificity (73%) and was significantly 
predictive of thrombus formation when compared to 
ejection fraction. Yuasa et al. found that the AUC analysis 
of a Tei index value ≥0.59 had similar AUC as ejection 
fraction <45% for 30-day complications (27). Zamfir et al. 
found that RV Tei index was the only parameter which 
significantly correlated with reinfarction, need for 
revascularisation and heart failure and death during the 
AMI hospitalisation (OR 9.17 95% CI 1.03–83.7) (29).
Discussion
Our review on Tei index and its predictive value in 
morbidity and mortality events in AMI patients have 
several key findings. First, several studies indicate that 
a greater Tei index value can predict morbidity and 
mortality events during both the initial hospitalisation 
period and follow-up period ranging from 30 days to 
57 months. Second, there is no consistency of what 
constituents a greater, or abnormal, Tei index value. The 
most appropriate timing of Tei index evaluation is also 
not known. Thirdly, it is not certain whether the use of 
the Tei index has any advantage over the more utilised 
echocardiographic measurement of LVEF and the more 
recent addition of global longitudinal strain imaging. 
More studies are needed in order to better understand 
Tei index before its routine incorporation into every day 
clinical practice.
The studies included in this review had several 
key differences making it challenging to assess the 
prognostic value of Tei index in AMI patients. Suggesting 
an appropriate ‘abnormal’ cut off value for Tei index is 
challenging for a number of reasons. First, in this review, 
Tei index values were assessed at varying times throughout 
the initial hospitalisation period with differing ‘abnormal’ 
cut of values being applied. Even in the five studies (6, 
19, 24, 26, 27), where Tei index was assessed within 24 
h of AMI ‘abnormal’ Tei index ‘abnormal’ values ranged 
from >0.60 (27), 0.686 ± 0.12 (24), >0.70 (26), and >0.73 
(6). Identifying an appropriate ‘abnormal’ Tei index cut 
Study ID
Tei index  
abnormal cut  
off values Tei index and outcomes Tei index prognostically useful?
Szymanski 2002 >0.55 Cardiac deaths and nonfatal recurrent  
myocardial infarction with Tei index >0.55  
aRR 4.45 (1.28–15.45), P = 0.019.
Yes, independent predictor for 
mortality or reinfarction. 




AMI patients (n = 77), controls (n = 88)
High (>0.60) vs low (<0.60) Tei index:
Death: 12 (30.8%) vs 1 (2.6%).
Heart failure: 19 (48.7%) vs 3 (7.9%).
Mean Tei index of surviving vs dead  
patients: 0.61 ± 0.1 vs 0.7 ± 0.1, P = 0.001.
Yes, indictor for development of 
heart failure, LV dysfunction and 
mortality.
Westholm 2013 N/A ROC analysis with AUC for Tei Index SD vs Tei Index 
Delta vs Simpson LVEF in respect to death: 0.65  
(0.56–0.74) vs 0.64 (0.55–0.73) vs 0.73 (0.65–0.81).
No, no significant prognostic 
information derived.
Yilmaz 2004 >0.60 Left ventricular thrombus formation prediction  
had a sensitivity of 81%, specificity of 73%,  
positive predictive value of 62%, negative  
predictive value of 88%. 
Yes, able to predict development 
of LV thrombus.
Yuasa 2005 >0.59 Multivariate predictors of complications (left  
ventricular aneurysm, heart failure, shock,  
paroxysmal atrial fibrillation, cardiac death,  
ventricular tachycardia/ventricular fibrillation,  
pericardial effusion, cardiac rupture,  
advanced atrioventricular block).
Yes, able to predict complications 
of AMI.
Zamfir 2016 N/A RV Tei index was the only parameter to  
correlated with major adverse cardiac events.
Yes, able to predict development 
of heart failure, reinfarction, 
need for re-vascularisation and 
mortality.
AUC, area under the curve; ROC, rceiver operating characteristics.
Table 3 Continued.
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off range in AMI patients is also further compounded by 
the fact that the original research, whereby a normal Tei 
index value of <0.39 ± 0.5 was derived, likely differs from 
the cohort of patients seen in this review. The original 
study by Tei et al. (1), was based on a cohort of 170 adult 
participants, 70 of which had a normal LVEF, whereas the 
remaining 100 participants were known to have a dilated 
cardiomyopathy of varying severities (LVEF ranging from 
30 to 50%), the breakdown of the underlying pathology, 
however, is not clear. Future studies are needed to clarify 
the optimal timing for when Tei index should be assessed 
along with systematically determining a Tei index 
‘abnormal’ cut off value which is best associated with 
adverse outcomes. The follow-up duration also varied 
vastly from the inclusion of the initial hospitalisation 
period only right up to 58 months post-AMI event. The 
use of different study end points was also apparent which 
included: mortality, reinfarction, left ventricular thrombus 
formation, tachyarrhythmia’s, bradyarrhythmia’s and 
heart failure episodes.
Current recommendations incorporate the use of 
LVEF and echocardiography assessment within 24–48 h 
of an AMI which enables patients to be risk-stratified and 
appropriately managed (9). Global longitudinal strain 
has also been shown to provide prognostic importance 
in AMI patients (30). However, the use of LVEF via 
Simpson’s biplane and global longitudinal strain is reliant 
on adequate 2D endocardial border definition in non-
foreshortened views. The Tei index is an easy measure of 
cardiac function which has the added advantage that it 
does not rely solely on adequate 2D image quality. This 
is important as Tei index could be used in patients where 
2D/3D LVEF or global longitudinal strain are impossible 
due to poor endocardial definition. Furthermore, LVEF is 
hinder by inter and intraobserver variability, geometric 
assumptions, is pre and after-load dependent and is affected 
by the presence of variable and high heart rates (30). 
While there is limited evidence about the inter-observer 
variability of the Tei index measurements, the inter-
observer variability is probably lower than that of either 
the left ventricular ejection fraction or global longitudinal 
strain measurements. Moreover, Tei index may be an 
attractive alternative quantification measurement as 
it has been shown to be independent of pre and after-
load, heart rate and geometric assumptions (15). Thus, 
Tei index has the potential to be a more reproducible and 
reliable quantification measure with the added benefit of 
not being heavily reliance on the endocardial definition 
and adequate 2D image quality. The appropriate timing of 
Tei index remains unknown, it is also unsure of whether a 
higher Tei index value would be required if evaluation is 
performed within the first 24–48 h post-AMI.
This review highlights the potential importance 
of an ‘abnormal’ Tei index value and its prognostic 
benefit to patients which is in keeping with the known 
prognostic value of Simpson’s biplane LVEF. There are 
some studies where the Tei index was found to be more 
sensitive, specific and accurate in comparison to LVEF 
in predicting morbidity and mortality events (6, 17, 27), 
however, each of these studies differed in terms of study 
end points, follow-up period as well as using differing 
Tei index cut off values. However, when a high Tei index 
was considered together with a reduced LVEF, there were 
studies to suggested Tei index does not yield additional 
prognostic information over LVEF alone. Nevertheless, 
when the LVEF was greater than 45% its prognostic value 
to predict adverse outcomes reliably is limited (31). The 
measurement of a ‘abnormal’ and high Tei index value 
in patients with mildly reduced or normal LVEF may 
highlight a previously undetected cohort of patients who 
are at a high risk of adverse events. Similarly, the finding 
of a reduced LVEF and low Tei index value may allow 
for further refinement in risk stratification of high-risk 
patients.
Studies have demonstrated myocardial recovery 
following an AMI event which can be easily detected with 
an improvement in Simpson’s biplane LVEF (9). There is 
limited information on whether Tei index showed a similar 
improvement over time. Hole et al. and Karvounis et al. 
were the only two studies which assessed Tei index at 
baseline and follow-up the results of both indicated there 
to be no significant change. This was also irrespective of 
whether Tei index was high or not at baseline (23, 24). 
The clinical relevance of an improvement in Tei index 
over time remains unknown.
Karvounis et al. (24) was the only study to report on 
the individual components of Tei index. In this study, 
there was no change in the isovolumetric relaxation 
time at baseline and at one-month follow-up, this was 
irrespective of whether there were signs of heart failure 
or not in the included patient cohort. This study did not 
evaluate isovolumetric contraction.
This review highlights the small number of fair 
and good quality studies investigating Tei index in AMI 
patients. The strengths of the review are that it included 
only full studies with abstracts and case reports being 
excluded and all studies were prospective in design with 
well-defined patient outcome end points. Several studies 
included all coronary territory AMI events with only three 
studies being selective of anterior or anteroseptal AMI’s. 
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This enables the results to be more applicable to a wider 
patient cohort. In addition, the studies are representative 
of the AMI cohort that is seen in clinical practice with 
a male predominance. Limitations of this review include 
the small sample sizes with the largest study involving 417 
patients, there were large variations in follow-up duration 
of patients. Patients were also managed differently 
which included being medically managed or receiving 
percutaneous coronary intervention which was performed 
either on admission or within 48 h of AMI event.
Several questions remain unanswered related to 
the role of Tei index in patients with AMI. Future 
large prospective studies should aim to determine an 
acceptable ‘abnormal’ cut off value for Tei index which is 
of a prognostic benefit to patients. The role of Tei index 
together with other measures such as 2D/3D LVEF and 
global longitudinal strain analysis in post-AMI patients 
merits further investigation over a short and long-term 
follow-up period. The importance of a greater high Tei 
index value in patients with mildly impaired or a normal 
LVEF and a low Tei index value in patients with moderate 
or severely impaired LVEF should be investigated. In 
addition, the prognostic value of right ventricular 
myocardial performance in AMI patients should also be 
evaluated.
In conclusion, the studies in the literature suggest 
that the Tei index has value in identifying patients who 
have a greater propensity for adverse events after AMI. 
However, more studies are needed to determine how Tei 
index should be used before its routine inclusion within 
the clinical practice as there is uncertainly to its additional 
value over well-established parameters such as LVEF.
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